In this study, the PARP-1 inhibitor AZD2281 showed in vitro synergetic effects in combination with cisplatin in three cell lines derived from oral carcinoma, HSC-2, Ca9-22 and SAS, and partly in vivo synergetic effects in xenografted HSC-2 tumors. The gene discussed is PARP1; the disease is lip and oral cavity carcinoma.